Genetic Analysis AS announced that the Company has successfully completed a pilot project and initiated a development project in collaboration with a global pharmaceutical company to develop a new microbiome-based rapid companion* diagnostic PCR test. The development project's goal is to provide clinicians with a decision tool for prescribing treatment and monitoring treatment effects aimed at faster clinical decision-making. A new microbiome diagnostic test providing rapid testing in human microbiomes is the goal as GA initiates a new development project with a leading global pharmaceutical company.

The project aims to provide increased standardization and potentially faster clinical decision -making at a low cost by developing GA's proprietary technology diagnostics platform GA-map® for use in a simple microbiome-based rapid PCR test. The collaboration partner is a leading pharmaceutical company with a high focus on gastroenterology. By combining the research and technology of the two companies into a simple microbiome-based rapid PCR test, clinicians will have a tool enabling patient stratification for treatment prescription and monitoring treatment effect.